Are there conditions where you would specifically favor using the subcutaneous over the IV formulation of pertuzumab/trastuzumab?
Conversely, is there any situation where you would prefer the IV over the subcutaneous formulation?
Answer from: Medical Oncologist at Academic Institution
With really long treatment programs like TCHP, utilizing SQ HP can really help cut down on infusion time, which is helpful as it allows a little more flexibility in booking the patients in the infusion center with regards to start times.
Answer from: Medical Oncologist at Community Practice
Specific conditions I favor nclude, but not limited to the following:
1. Patient is receiving a non-IV containing regimen
2. Patient has limited peripheral access or no central access
3. Patient has a current central access that poses an infection risk or otherwise has an indica...